Mixture Cure Models in Oncology: A Tutorial and Practical Guidance

Abstract

Novel cancer therapies are associated with survival patterns that differ from established therapies, which may include survival curves that plateau after a certain follow-up time point. A fraction of the patient population is then considered statistically cured and subject to the same mortality experience as the cancer-free general population. Mixture cure models have been developed to account for this characteristic. As compared to standard survival analysis, mixture cure models can often lead to profoundly different estimates of long-term survival, required for health economic evaluations. This tutorial is designed as a practical introduction to mixture cure models. Step-by-step instructions are provided for the entire implementation workflow, i.e., from gathering and combining data from different sources to fitting models using maximum likelihood estimation and model results interpretation. Two mixture cure models were developed to illustrate (1) an "uninformed" approach where the cure fraction is estimated from trial data and (2) an “informed” approach where the cure fraction is obtained from an external source (e.g., real-world data) used as an input to the model. These models were implemented in the statistical software R, with the freely available code on GitHub. The cure fraction can be estimated as an output from (“uninformed” approach) or used as an input to (“informed” approach) a mixture cure model. Mixture cure models suggest presumed estimates of long-term survival proportions, especially in instances where some fraction of patients is expected to be statistically cured. While this type of model may initially seem complex, it is straightforward to use and interpret. Mixture cure models have the potential to improve the accuracy of survival estimates for treatments associated with statistical cure, and the present tutorial outlines the interpretation and implementation of mixture cure models in R. This type of model will likely become more widely used in health economic analyses as novel cancer therapies enter the market. Supplementary Information The online version contains supplementary material available at 10.1007/s41669-021-00260-z.

Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial

“…The data presented here were analysed using R software with code: Felizzi/Cure_Models: Cure_Models_Tutorial. 2018: Zenodo [22]. A tutorial and practical guidance on this methodology has been reported separately [23].…”

Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors

“…[8][9][10] A fraction of the patients' population could be then considered potentially cured and, from a statistical point of view, may be subject to the same mortality of the cancer-free general population. 15 Therefore, mixture cure models have been proposed as an alternative to traditional proportional hazard models, as the Cox model, to explore the association between survival endpoints and putative prognostic factors in a multivariable context. The advantage of cure models relies on the assumption of two different populations of patients: those who are cured and those who are 'not cured', thus allowing the identification of patients at high chance to be alive and event-free independently of time.…”

Analysis of survival outcomes in haematopoietic cell transplant studies: Pitfalls and solutions

“…These changes in impact can be accommodated within the Cox model by modelling time-dependent HRs or by stratification (estimating baseline hazards separately for different groups while assuming the effect of other covariates to be the same). Also other models exist that are more suitable for long-term outcomes, such as cure models [31] and models incorporating general population mortality (relative survival) [32,21].…”